STAT

A Chinese company unveils a powerful new sequencer. But can it compete in the U.S.?

A new genome sequencer from China can generate six terabytes of data in a day — about as much data as a person would use watching Netflix non-stop for half…
A lab worker performs DNA tests at the Beijing Genomics Institute in 2005. The operation evolved into BGI.

Nearly two years ago, the San Diego-based genomics giant Illumina reaffirmed its dominance of the DNA sequencing market when it announced a fast and powerful new machine, called the NovaSeq, that’s since been adopted in labs all over the world.

On Thursday, at a genomics conference in China, a Chinese company called BGI unveiled its own new machine. That machine, the company said, can sequence a whole genome in 24 hours. It can generate six terabytes of sequencing data — about as much data as a person would use watching Netflix nonstop for half a year — over that period. And, again, according to the company, it can do it all with the utmost precision.

All of which could, at the right price, make BGI a very fierce competitor for Illumina — and possibly drive the already-plummeting cost of sequencing down even further.

“It seems that the race is on, and geneticists everywhere are the big winners,” said Christopher Mason, a geneticist at Weill Cornell Medicine.

The race is being closely watched by scientists and clinicians. Cheaper, faster sequencers,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks